Venetoclax-rituximab ± bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma: CONTRALTO


Blood. 2020 Aug 12:blood.2020005588. doi: 10.1182/blood.2020005588. Online ahead of print.


This open-label phase 2 study (CONTRALTO) assessed the safety and efficacy of BCL-2 inhibitor venetoclax (VEN) plus rituximab (R), and VEN plus bendamustine (B) and R, versus BR alone in relapsed/refractory follicular lymphoma. Patients in the chemotherapy-free arm (Arm A: VEN+R) received VEN 800 mg/d plus R 375 mg/m2 on days (D) 1, 8, 15, and 22 of cycle (C)1 and D1 of C4, C6, C8, C10, and C12. After a safety run-in with VEN 600 mg, patients in the chemotherapy-containing cohort were randomized

to either VEN+BR (Arm B; VEN 800 mg/d for 1 year + 6 cycles BR [B 90 mg/m2 D1, 2 and R 375 mg/m2 D1]) or 6 cycles BR (Arm C). Overall, 163 patients were analyzed: 9 in safety run-in; 52, 51, and 51 in Arms A, B, and C, respectively. Complete metabolic/complete response rates were 17% (Arm A), 75% (Arm B), and 69% (Arm C). Of patients in Arm B, only 61% received ≥90% of the planned bendamustine dose versus 96% of patients in Arm C. More frequent hematologic toxicity resulted in more reduced dosing/treatment discontinuation in Arm B versus C. Rates of grade 3/4 adverse events were 51.9%, 93.9% and 60.0% in Arms A, B and C, respectively. VEN+BR led to increased toxicity and lower dose intensity of BR than in Arm C, but efficacy was similar. Optimizing dose and schedule to maintain BR dose intensity may improve efficacy and tolerability of VEN+BR, while VEN+R data warrant further study (NCT02187861;